AVVAA World Health Care Products, Inc (AVVH) fair value: what the stock is really worth
As of Oct 19, 2026: fair value (intrinsic value) of AVVAA World Health Care Products, Inc stock $0.00, price $0.00, upside +3.4%, quality 48 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
AVVAA World Health Care Products, Inc. provides natural and therapeutic skin care products worldwide.
Show moreShow less
The company is a biotechnology company which primarily focuses on manufacturing and marketing over-the-counter the Neuroskin line of products used for the treatment of skin abnormalities, and to enhance the natural clarity and texture of healthy skin through mass marketing food and drug channels.
It also has distribution rights for patented European skin care products, which are scientifically developed to treat the symptoms of skin diseases, including eczema, psoriasis, and acne.
The company also offers a line of natural animal care products, which is a grooming treatment for dogs, cats, horses, and other pets. AVVAA World Health Care Products, Inc. was incorporated in 1998 and is based in Richmond, Virginia.
As of June 23, 2021, AVVAA World Health Care Products, Inc. operates as a subsidiary of Gold Quest Capital, Inc.
Stock analysis
AVVAA World Health Care Products, Inc (AVVH) currently trades at $0.0035, while our model-based Fair Value estimate is $0.0036, so the stock looks roughly fairly valued today (gap 3.3%).
Show more
Valuation
How firm this estimate is: it rests on 13 models at a data quality of 96/100, which puts the data coverage at low.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Financial Services sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
AVVAA World Health Care Products, Inc reported revenue of $158K in FY2026 versus $13.5K in FY2012, a compound +19.2%/yr. Reported net income was −$18.5K in FY2026.
Key figures
Market cap $3.4M Micro · P/S ratio 90.3 · EPS (TTM) $−35.00 · Net margin −11.7% · Return on assets (EBIT) −8.2% · Operating margin −5,836% · Revenue growth (YoY) +45.9% · Free cash flow $32.7K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 250% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at 14% fair-value upside, at 3%, AVVH screens richer than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.78/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3,294.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+329.0%
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.4%
’04
’05
’06
’07
’08
’10
’11
’12
’13
’23
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,433.5% (2008) → 3.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+63.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +59.8% a year for the price.
Compare AVVAA World Health Care Products, Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Mortgage Finance · 61 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+3.4% · Below median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−1.1% · Bottom 25%
Net margin (12 months)−11.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)45.9% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Mortgage Finance median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "AVVAA World Health Care Products, Inc Fair Value". https://www.fairvalue-calculator.com/stock/AVVH
Frequently asked questions
Is AVVAA World Health Care Products, Inc (AVVH) overvalued or undervalued?
As of Oct 21, 2026, our model estimates a fair value of $0.0036 versus a price of $0.0035, about +3% upside (fairly valued).
What is the fair value of AVVH?
Our model-based fair value for AVVAA World Health Care Products, Inc is $0.0036 (as of Oct 21, 2026), built from audited fundamentals. The current price: $0.0035.
What is the quality score of AVVH?
AVVAA World Health Care Products, Inc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AVVAA World Health Care Products, Inc (AVVH)?
Our model-based price target is the fair value of $0.0036 (as of Oct 21, 2026) from 3 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the AVVAA World Health Care Products, Inc stock forecast for 2026?
Our models put fair value at $0.0036, about +3% upside versus a price of $0.0035 (fairly valued). The calculation is refreshed regularly with new filings.
What growth is priced into AVVAA World Health Care Products, Inc (AVVH)?
For today's price to be fair in a discounted-cash-flow model, AVVAA World Health Care Products, Inc would have to grow free cash flow by +63.6 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 13 years revenue grew +12.9 % per year. As of Oct 21, 2026.
What discount rate (WACC) does the fair value of AVVH use?
Our models discount AVVAA World Health Care Products, Inc at 9.6 %: a base by market capitalisation (nano), damped by beta 0.94, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AVVAA World Health Care Products, Inc that is +63.6 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has AVVAA World Health Care Products, Inc (AVVH) delivered so far?
Over the past 13 years revenue at AVVAA World Health Care Products, Inc grew +12.9 % a year. The price currently implies +63.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AVVAA World Health Care Products, Inc (AVVH) growing?
The median revenue growth in the sector is +9.3 % a year. That is the yardstick for the growth priced into AVVAA World Health Care Products, Inc (+63.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AVVAA World Health Care Products, Inc (AVVH)?
The free-cash-flow yield on the price is 0.97 %: that much free cash flow AVVAA World Health Care Products, Inc produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AVVAA World Health Care Products, Inc (AVVH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AVVAA World Health Care Products, Inc it is $0.0036 per share (as of Oct 21, 2026), against a price of $0.0035. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is AVVAA World Health Care Products, Inc stock overvalued or undervalued in 2026?
As of Oct 21, 2026, AVVH trades below its calculated fair value: price $0.0035, fair value $0.0036, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVVH?
No. The price is what the market pays today ($0.0035); the fair value is what the company's own numbers justify ($0.0036). For AVVAA World Health Care Products, Inc the two are $0.0001 per share apart. That gap is exactly why we show both numbers side by side.
How much is AVVAA World Health Care Products, Inc worth?
The market values AVVAA World Health Care Products, Inc at about $3.4M (market capitalisation, as of Oct 21, 2026). Per share that is $0.0035; our models calculate a fair value of $0.0036 per share.
How solid is the balance sheet of AVVAA World Health Care Products, Inc (AVVH)?
Balance-sheet figures for AVVAA World Health Care Products, Inc (as of Oct 21, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is AVVH from its 52-week high?
AVVAA World Health Care Products, Inc trades at $0.0035, about 26% below its 52-week high of $0.0047 and 250% above the low of $0.0010 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0036 is for.
Which stocks are comparable to AVVAA World Health Care Products, Inc?
From the same area (Financial Services) we also value Rocket Companies, Inc, Bajaj Housing Finance Limited, Federal Home Loan Mortgage Corporation, Federal National Mortgage Association, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AVVAA World Health Care Products, Inc stock attractive at the current price?
The data as of Oct 21, 2026: price $0.0035, calculated fair value $0.0036 (+3%), Quality Score 48/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AVVH calculated?
We run AVVAA World Health Care Products, Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0036, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6 % above its aggregate fair value. AVVAA World Health Care Products, Inc currently trades 3 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AVVAA World Health Care Products, Inc (AVVH)?
The closing price on Oct 19, 2026 was $0.0035. Our model-based fair value is $0.0036, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AVVAA World Health Care Products, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Key figures of AVVAA World Health Care Products, Inc
How large is the market capitalisation of AVVAA World Health Care Products, Inc (AVVH)?
The market capitalisation of AVVAA World Health Care Products, Inc is $3.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AVVAA World Health Care Products, Inc (AVVH)?
The price-to-sales ratio of AVVAA World Health Care Products, Inc is 90.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AVVAA World Health Care Products, Inc (AVVH)?
Earnings per share at AVVAA World Health Care Products, Inc are $−35.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of AVVAA World Health Care Products, Inc (AVVH)?
The net margin of AVVAA World Health Care Products, Inc is −11.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of AVVAA World Health Care Products, Inc (AVVH)?
On an EBIT basis the return on assets of AVVAA World Health Care Products, Inc is −8.2% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AVVAA World Health Care Products, Inc (AVVH)?
The operating margin of AVVAA World Health Care Products, Inc is −5,836% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AVVAA World Health Care Products, Inc (AVVH)?
Revenue at AVVAA World Health Care Products, Inc is growing +45.9% versus a year earlier (3y avg +69.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does AVVAA World Health Care Products, Inc (AVVH) carry?
The net debt of AVVAA World Health Care Products, Inc is $1.5M (fiscal year 2026, ≈ 44.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch AVVAA World Health Care Products, Inc in the live analysis
One click puts AVVAA World Health Care Products, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 21, 2026